Early Prediction of Therapy Outcome in Patients with High-Risk Soft Tissue Sarcoma Using Positron Emission Tomography

Onkologie ◽  
2008 ◽  
Vol 31 (3) ◽  
pp. 107-112 ◽  
Author(s):  
Bernd Kasper ◽  
Sascha Dietrich ◽  
Antonia Dimitrakopoulou-Strauss ◽  
Ludwig G. Strauss ◽  
Uwe Haberkorn ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Emission Tomography ◽  
Therapy Outcome ◽  
Early Prediction ◽  
Positron Emission

Can we predict therapy outcome in patients with high risk soft tissue sarcoma using positron emission tomography?

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 20511-20511
Author(s):  
B. Kasper ◽  
A. Dimitrakopoulou-Strauss ◽  
P. Wuchter ◽  
G. Egerer ◽  
A. D. Ho
Keyword(s):  
Positron Emission Tomography ◽  
Discriminant Analysis ◽  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Soft Tissue Sarcomas ◽  
Magnetic Resonance Tomography ◽  
Emission Tomography ◽  
Therapy Outcome ◽  
Positron Emission

20511 Background: We used 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography (FDG) studies to evaluate the FDG metabolism kinetics in patients (pts.) with high risk soft tissue sarcomas receiving an induction or neoadjuvant chemotherapy. The treatment effect was assessed with regard to the prediction of therapy outcome. Methods: The ongoing evaluation includes 25 pts. with high grade soft tissue sarcoma with different histologies: 14 pts. received an induction chemotherapy consisting of adriamycin 75 mg/m2/day 1 and ifosfamide 1500 mg/m2/day 1–4 (AI-G regimen, six cycles) prior to peripheral blood stem cell transplantation, and 11 pts. were treated with pre-operative chemotherapy consisting of etoposide 125 mg/m2/day 1+4, ifosfamide 1500 mg/m2/day 1–4 and doxorubicin 50 mg/m2/day 1 (EIA regimen, 4 cycles). Pts. were examined prior to onset of therapy and after completion of the first cycle of AI-G and after two cycles of EIA chemotherapy, respectively. The restaging data of 21 patients (11 pts with AI-G and 10 patients with EIA treatment) served for reference. Restaging was performed using computed tomography and magnetic resonance tomography after six cycles of AI-G or four cycles of EIA chemotherapy. Results: 21 pts. were evaluable by the time of data evaluation. According to RECIST criteria, clinical outcome was as follows: 3 pts. showed no evidence of disease (NED), 6 partial remissions (PR), 5 stable diseases (SD), and 7 pts. with progressive disease (PD). Due to the small number of pts., we dichotomized the data in pts. with NED/PR (n = 9) and pts. with SD/PD (n = 12). Median average standard uptake value (SUV) prior therapy was 5.4 in comparison to 4.1 after chemotherapy. Median maximum SUV was 8.3 prior to chemotherapy in comparison to 6.6 following therapy. We used discriminant analysis and four predictor variables, namely the average and maximum SUV of both the baseline and the follow-up study to classify the pts. into responders and non-responders. Discriminant analysis revealed a correct classification rate of 70 %. Conclusions: On the basis of these data, prediction of chemo-sensitivity of the tumor and moreover of the therapy outcome might be possible. No significant financial relationships to disclose.

Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients

2001 ◽  
Vol 19 (14) ◽  
pp. 3397-3405 ◽  
Author(s):  
Brian H. Kushner ◽  
Henry W.D. Yeung ◽  
Steven M. Larson ◽  
Kim Kramer ◽  
Nai-Kong V. Cheung
Keyword(s):  
Positron Emission Tomography ◽  
High Risk ◽  
Soft Tissue ◽  
Imaging Modality ◽  
Emission Tomography ◽  
Cranial Vault ◽  
Positron Emission ◽  
Abdominal Masses ◽  
Minimum Number ◽  
Fluorine 18 Fluorodeoxyglucose

PURPOSE: Although positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (18F-FDG) has a major impact on the treatment of adult cancer, the reported experience with extracranial tumors of childhood is limited. We describe a role for PET in patients with neuroblastoma (NB). PATIENTS AND METHODS: In 51 patients with high-risk NB, 92 PET scans were part of a staging evaluation that included iodine-123 or iodine-131 metaiodobenzylguanidine (MIBG) scan, bone scan, computed tomography (and/or magnetic resonance imaging), urine catecholamine measurements, and bone marrow (BM) examinations. The minimum number of tests sufficient to detect NB was determined. RESULTS: Of 40 patients who were not in complete remission, only 1 (2.5%) had NB that would have been missed had a staging evaluation been limited to PET and BM studies, and 13 (32.5%) had NB detected by PET but not by BM and urine tests. PET was equal or superior to MIBG scans for identifying NB in soft tissue and extracranial skeletal structures, for revealing small lesions, and for delineating the extent and localizing sites of disease. In 36 evaluations of 22 patients with NB in soft tissue, PET failed to identify only two long-standing MIBG-negative abdominal masses. PET and MIBG scans showed more skeletal lesions than bone scans, but the normally high physiologic brain uptake of FDG blocked PET visualization of cranial vault lesions. Similar to MIBG, FDG skeletal uptake was diffusely increased with extensive or progressing BM disease but faint or absent with minimal or nonprogressing BM disease. CONCLUSION: In the absence or after resolution of cranial vault lesions, and once the primary tumor is resected, PET and BM tests suffice for monitoring NB patients at high risk for progressive disease in soft tissue and bone/BM.

scholarly journals Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy

Cancer ◽  
2005 ◽  
Vol 103 (2) ◽  
pp. 339-348 ◽  
Author(s):  
Scott M. Schuetze ◽  
Brian P. Rubin ◽  
Cheryl Vernon ◽  
Douglas S. Hawkins ◽  
James D. Bruckner ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
Emission Tomography ◽  
Positron Emission ◽  
Extremity Soft Tissue Sarcoma

scholarly journals 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma

Cancer ◽  
2011 ◽  
Vol 118 (12) ◽  
pp. 3135-3144 ◽  
Author(s):  
Matthias R. Benz ◽  
Johannes Czernin ◽  
Martin S. Allen-Auerbach ◽  
Sarah M. Dry ◽  
Piriya Sutthiruangwong ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Response Assessment ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin

Marine Drugs ◽  
2009 ◽  
Vol 7 (3) ◽  
pp. 331-340 ◽  
Author(s):  
Bernd Kasper ◽  
Thomas Schmitt ◽  
Patrick Wuchter ◽  
Antonia Dimitrakopoulou-Strauss ◽  
Anthony Ho ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Emission Tomography ◽  
Positron Emission

Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose

1997 ◽  
Vol 4 (1) ◽  
pp. 57-63 ◽  
Author(s):  
Annemieke C. Kole ◽  
Omgo E. Nieweg ◽  
Robert J. van Ginkel ◽  
Jan Pruim ◽  
Harald J. Hoekstra ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Soft Tissue ◽  
Local Recurrence ◽  
Soft Tissue Sarcoma ◽  
Emission Tomography ◽  
18F Fluorodeoxyglucose ◽  
Positron Emission
Sign in / Sign up

Export Citation Format

Share Document